NCT07251998RecruitingPhase 2
Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2 Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ICP-332 in Patients With Moderate to Severe Plaque Psoriasis
Source: ClinicalTrials.gov · Last updated 31 Dec 2025
Brief summary (registry, in English)
The purpose of this study is to compare the efficacy and safety of ICP-332 to placebo in participants with moderate-to-severe plaque psoriasis.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 172 (estimated)
- First submitted
- 19 Nov 2025
- Start date
- 22 Dec 2025
- Primary completion date
- 31 Oct 2026
- Lead sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Diseases
- Psoriasis
- NCT number
- NCT07251998
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 172
- From 22 Dec 2025 to the primary completion date, 31 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous history of alcoholism or drug abuse (except for those who have been completely abstinent for more than 6 months before randomization).
Other illness
- Presence of clinically serious, progressive, or uncontrolled disease.
Lab values
- Subject had laboratory values meeting any of the protocol-specified criteria at Screening.
Other
- Diagnosed with non-plaque psoriasis.
- Pregnant or lactating women.
- The investigator accepts ICP-332 for any reason that the subject is not suitable for this study.
Who the study is looking for
- Subjects voluntarily participate in this study and have signed the Informed Consent Form (ICF).
- Male or female subjects aged ≥ 18 years and ≤ 70 years
- A history of plaque psoriasis for ≥6 months at baseline
- Meet the following three criteria:
- Psoriasis Area and Severity Index (PASI) score ≥12
- Static Physician's Global Assessment (sPGA) score ≥3
- Psoriasis affected Body Surface Area (BSA) ≥10%
- The subject requires systemic treatment and/or phototherapy.
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai Dermatology Hospital Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.